US74365N2027 - Common Stock
2.04 -0.09 (-4.23%)
After market: 2.01 -0.03 (-1.47%)
Protagenic Therapeutics (PTIX) on Wednesday announced it has approved a 1-for-4 reverse stock split of the company's issued and outstanding common stock.
We're starting the week with a breakdown of the biggest pre-market stock movers traders need to know about for Monday morning!
NEW YORK, NY / ACCESSWIRE / April 26, 2022 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX) a biopharmaceutical company focused on developing drug product candidates to treat stress-related neurologic disorders, today announced will be presenting at the B. Riley Securities Neuro and Ophthalmology Virtual Investor Conference tomorrow, April 27, 2022. The presentation details are as follows: Date: Wednesday, April 27, 2022 Time: 10:30 AM ET Link:
NEW YORK, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Protagenic Therapeutics, Inc. (Nasdaq: PTIX) a biopharmaceutical company focused on developing therapies to...
RALEIGH, NC / ACCESSWIRE / July 8, 2021 / Access to Giving - an investor conference themed around investor education and advocacy begins next week, July 13th - 15th, 2021. More than 50 companies are scheduled to conduct virtual presentations over the three-day period as well as 1x1 meetings with qualified investors throughout the event. John Hope Bryant, guest host on CNBC and CEO of Operation HOPE will deliver the keynote to kick off the
RALEIGH, NC / ACCESSWIRE / June 23, 2021 / Access to Giving - an investor conference themed around investor education and advocacy is set for July 13-15, 2021. There will be 50+ companies conducting virtual presentations as well as private meetings with qualified investors throughout the three-day event. Company Presentations will begin July 13 at 10 am eastern time and go through July 15th. The event will also include a keynote speaker (to be